Yazar "Çelik, Emir" seçeneğine göre listele

Listeleniyor 1 - 3 / 3
  • Küçük Resim Yok
    Öğe
    FACTORS OF AFFECTING SLEEP QUALITY IN CANCER PATIENTS
    (2020) Samancı, Nilay Şengül; Çelik, Emir; Değerli, Ezgi; Oruç, Kerem; Bedir, Şahin; Derin, Sümeyra; Öztaş, Nihan Şentürk
    Aim: Sleep disorders are one of the most common problems in patients with malignancy and they severely decrease the quality of life.We sought to investigate the frequency of sleep disturbances, its quantity, quality and possible correlation with related factors such asdepression and anxiety.Materials and Methods: 150 patients participated and the Pittsburgh Sleep Quality Index was used to evaluate the sleep quality. It is aself-administered questionnaire and standardized measure of sleep quality. Total score of ?5 shows that the quality of sleep isremarkably bad. Also a self-report measure of depression, the Beck Depression Inventory (BDI); and a self-report measure of anxiety,Beck Anxiety Inventory (BAI) were used.Results: Of the 150 patients, 74.0% has bad sleep quality (score >5 ). Mean PSQI total score was 7.34 (min 0-max 20). No differenceswere found between PSQI mean scores in terms of gender, radiotherapy (RT), chemotherapy (CHT), having chronic disease or havingmetastatic disease. NSAIDs and opioids were significantly correlated with PSQI (p<0.001). PSQI total scores are strongly associatedwith the BDI score (r=.424, p<0.001) and BAI score (r=.417, p<0.001).Conclusion: We found a high prevalence rate of bad sleep quality at 74%. Effective sleep treatment and psychological support shouldbe provided in oncology clinics.
  • Küçük Resim
    Öğe
    Real-life comparison of afatinib and erlotinib in non-small cell lung cancer with rare EGFR exon 18 and exon 20 mutations: a Turkish Oncology Group (TOG) study
    (Springer, 2022) Gürsoy, Pınar; Tatlı, Ali Murat; Erdem, Dilek; Göker, Erdem; Çelik, Emir; Demirci, Nebi Serkan; Yumuk, Perran Fulden; Çavdar, Eyyüp
    Objectives To compare the survival of first- and second-generation tyrosine kinase inhibitors (TKIs) in patients with rare EGFR exon 18 and exon 20 mutation-positive non-small cell lung cancer (NSCLC). Materials and methods We retrospectively evaluated survival characteristics of 125 patients with EGFR exon 18 and exon 20 mutated NSCLC who received erlotinib or afatinib as first line treatment between 2012 and 2021 from 34 oncology centres. Since exon 20 insertion is associated with TKI resistance, these 18 patients were excluded from the study. Results EGFR exon 18 mutations were seen in 60%, exon 20 mutations in 16%, and complex mutations in 24% of the patients with NSCLC who were evaluated for the study. There were 75 patients in erlotinib treated arm and 50 patients in afatinib arm. Patients treated with erlotinib had progression-free survival time (PFS) of 8.0 months and PFS was 7.0 months in the afatinib arm (p = 0.869), while overall survival time (OS) was 20.0 vs 24.8 months, respectively (p = 0.190). PFS of exon 18 mutated arm was 7.0 months, exon 20 mutated arm was 4.3 months, and complex mutation positive group was 17.3 months, and this was statistically significant (p = 0.036). The longest OS was 32.5 months, seen in the complex mutations group, which was not statistically different than exon 18 and in exon 20 mutated groups (21.0 and 21.2 months, respectively) (p = 0.323). Conclusion In this patient group, especially patients with complex mutations are as sensitive to EGFR TKI treatment similar to classical mutations, and in patients with rare exon 18 and exon 20 EGFR mutation both first- and second-generation EGFR-TKIs should be considered, especially as first- and second-line options.
  • Küçük Resim
    Öğe
    Real-life comparison of the afatinib and first-generation tyrosine kinase inhibitors in nonsmall cell lung cancer harboring EGFR exon 19 deletion: a Turk Oncology Group (TOG) study
    (Springer, 2021) Bilgin, Burak; Sendur, Mehmet Ali; Yücel, Şebnem; Çelik, Emir; Özyükseler, Deniz Tataroğlu; Ayhan, Murat; Yalçın, Bülent; Avcı, Okan
    Background The new second-generation tyrosine kinase inhibitors (TKIs) have superior survival outcome and worse toxicity profile when compared with first-generation TKIs according to the results of clinical trials. However, there are limited studies that investigate the efficacy and safety of the new generation TKIs in real-world patients. Thus, we aimed to compare the efficacy and safety of the afatinib, an irreversible inhibitor of ErbB family receptor, and first-generation TKIs in real-world patients. Materials and methods We included advanced nonsmall cell lung cancer (NSCLC) patients who had EGFR exon 19del mutation and treated with afatinib or first-generation TKIs as upfront treatment between 2016 and 2020. All patient's information was collected retrospectively. The study cohort was divided as afatinib arm and erlotinib/gefitinib arm. Results A total of 283 patients at the 24 oncology centers were included. The 89 and 193 of whom were treated with afatinib and erlotinib/gefitinib, respectively. After 12.9 months (mo) of follow-up, the median PFS was statistically longer in the afatinib arm than erlotinib/gefitinib arm (19.3 mo vs. 11.9 mo, p: 0.046) and the survival advantage was more profound in younger patients (< 65 years). The 24-mo overall survival rate was 76.1% and 49.5% in the afatinib arm and erlotinib/gefitinib arm, respectively. Although all-grade adverse event (AE) rates were similar between the two arms, grade 3-4 AE rates were higher in the afatinib arm (30.7% vs. 15.2%; p: 0.004). Discussion In our real-world study, afatinib has superior survival outcomes despite worse toxicity profile as inconsistent with clinical study results and it is the good upfront treatment option for younger patients and elderly patients who have good performance status.